Dietary Fatty Acid Composition and Obesity-related Metabolic Abnormalities
Assessing the Effects of Two Diets Enriched in Either Saturated or Unsaturated Fatty Acids to Determine the Cellular and Molecular Mechanisms in Insulin Sensitivity
1 other identifier
interventional
40
1 country
1
Brief Summary
Individuals have a significant capacity to adapt to different environments by changing their core metabolic pathways. This adaptation is especially important in regards to diet. Epidemiological research over the last several decades have shown that diets high in saturated fats have a greater ability to cause insulin resistance and the 'metabolic syndrome' while diets low in saturated fats (or a so called 'Mediterranean Diet), reduces the risk for cardiovascular disease. In humans, experimental diets high in unsaturated fats, as compared to high carbohydrate or high saturated fat diets, result in increased insulin sensitivity and improved lipid profiles. In this application, the investigators propose to systematically assess the effects of two diets enriched in either saturated or unsaturated fatty acids and determine the cellular and molecular mechanisms of the apparent increase in insulin sensitivity. The investigators hypothesize that individuals will 'adapt' to the different diets and the investigators will be able to generate predictive alterations in gene expression and metabolites that underlie the alterations in metabolism. In parallel, the investigators will test the ability of these different diets to affect the release of gastrointestinal hormones that may be critical to modulation of appetite.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2007
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 12, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
December 12, 2010
CompletedFirst Submitted
Initial submission to the registry
October 11, 2011
CompletedFirst Posted
Study publicly available on registry
October 14, 2011
CompletedMarch 21, 2022
March 1, 2022
3.4 years
October 11, 2011
March 18, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Insulin Sensitivity
A hyperinsulinemic-euglycemic clamp will be used to assess insulin sensitivity.
2-3 hours
Secondary Outcomes (1)
Resting Metabolic Rate
20-30 min
Study Arms (2)
High Monounsaturated Fat Diet
OTHERSubjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated.
High Saturated Fat Diet
OTHERSubjects will adhere to their specific diet for four weeks. The diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
Interventions
Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
Eligibility Criteria
You may qualify if:
- Premenopausal females with BMI range of 25-32 kg/m2
You may not qualify if:
- Evidence of metabolic or cardiovascular disease, Fasting plasma glucose concentration \> 125mg/dl, Abnormal EKG, Hyperlipidemia (plasma triglyceride concentration \> 150mg/dl), Pregnancy, Hematocrit \<34%
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Michiganlead
- Robert C. Atkins Foundationcollaborator
Study Sites (1)
Michigan Clincal Research Unit
Ann Arbor, Michigan, 48109, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jeffrey F Horowitz, Ph.D.
University of Michigan
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor, Movement Science, School of Kinesiology
Study Record Dates
First Submitted
October 11, 2011
First Posted
October 14, 2011
Study Start
August 1, 2007
Primary Completion
December 12, 2010
Study Completion
December 12, 2010
Last Updated
March 21, 2022
Record last verified: 2022-03